These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 37080927)

  • 1. Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin.
    Liang L; Li W; Zhang Z; Li D; Pu S; Xiang R; Zhai F
    Biopharm Drug Dispos; 2023 Jun; 44(3):245-258. PubMed ID: 37080927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.
    Hornik CP; Wu H; Edginton AN; Watt K; Cohen-Wolkowiez M; Gonzalez D
    Clin Pharmacokinet; 2017 Nov; 56(11):1343-1353. PubMed ID: 28290120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Pediatric Rectal Absorption, Drug Disposition, and Sedation Level for Midazolam Gel Using Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling.
    Zhu J; Zhou S; Wang L; Zhao Y; Wang J; Zhao T; Li T; Shao F
    Mol Pharm; 2024 May; 21(5):2187-2197. PubMed ID: 38551309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of Physiologically Based Pharmacokinetic Model of Levetiracetam to Predict Exposure and Dose Optimization in Pediatrics.
    Shao W; Shen C; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
    J Pharm Sci; 2023 Oct; 112(10):2667-2675. PubMed ID: 37023853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children.
    Ince I; Dallmann A; Frechen S; Coboeken K; Niederalt C; Wendl T; Block M; Meyer M; Eissing T; Burghaus R; Lippert J; Willmann S; Schlender JF
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1(Suppl 1):S70-S82. PubMed ID: 34185905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.
    Maglalang PD; Sinha J; Zimmerman K; McCann S; Edginton A; Hornik CP; Hornik CD; Muller WJ; Al-Uzri A; Meyer M; Chen JY; Anand R; Perrin EM; Gonzalez D;
    Clin Pharmacokinet; 2024 Jun; 63(6):885-899. PubMed ID: 38814425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling.
    Guan R; Li X; Ma G
    Front Pharmacol; 2023; 14():1326373. PubMed ID: 38089044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic Model for Older Adults and Its Application in Geriatric Drug Research.
    Wu X; Sia JEV; Hai M; Lai X; Li H; Cui C; Liu D
    Curr Drug Metab; 2023; 24(3):211-222. PubMed ID: 37165496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing Dose-Exposure-Response Relationships of Miltefosine in Adults and Children using Physiologically-Based Pharmacokinetic Modeling Approach.
    Madu SJ; Wang K; Chirumamilla SK; Turner DB; Steel PG; Li M
    Pharm Res; 2023 Dec; 40(12):2983-3000. PubMed ID: 37816929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Individualized Medication of Azithromycin for Injection in Children Under 6 Years Old.
    Zhang Y; Wang Y; Li J; Wang H; Hou M; Dong R; Li X
    J Pharm Sci; 2024 May; 113(5):1351-1358. PubMed ID: 38253224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBPK Modeling of Azithromycin Systemic Exposure in a Roux-en-Y Gastric Bypass Surgery Patient Population.
    Avvari SK; Cusumano JA; Jogiraju VK; Manchandani P; Taft DR
    Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia.
    Kalsoom S; Rasool MF; Imran I; Saeed H; Ahmad T; Alqahtani F
    Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Mechanistic Physiologically-Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers.
    Zhang X; Lumen A; Wong H; Connarn J; Dutta S; Upreti VV
    Clin Pharmacol Ther; 2024 Mar; 115(3):457-467. PubMed ID: 37746860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.
    Morcos PN; Schlender J; Burghaus R; Moss J; Lloyd A; Childs BH; Macy ME; Reid JM; Chung J; Garmann D
    Clin Transl Sci; 2023 Jul; 16(7):1197-1209. PubMed ID: 37042099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-Based Pharmacokinetic Modeling and Dosing Optimization of Cefotaxime in Preterm and Term Neonates.
    Li Q; Guan Y; Xia C; Wu L; Zhang H; Wang Y
    J Pharm Sci; 2024 Aug; 113(8):2605-2615. PubMed ID: 38460573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBPK/PD Modeling of Nifedipine for Precision Medicine in Pregnant Women: Enhancing Clinical Decision-Making for Optimal Drug Therapy.
    Liu X; Wang W; Chen J; Chen D; Tao Y; Ouyang D
    Pharm Res; 2024 Jan; 41(1):63-75. PubMed ID: 38049651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by Modeling and Simulation.
    Verscheijden LFM; van der Zanden TM; van Bussel LPM; de Hoop-Sommen M; Russel FGM; Johnson TN; de Wildt SN
    Clin Pharmacol Ther; 2020 Aug; 108(2):248-252. PubMed ID: 32320477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Modeling of Bepotastine for Determination of Optimal Dosage Regimen in Pediatric Patients with Allergic Rhinitis or Urticaria.
    Yoon S; Jin BH; Kim CO; Park K; Park MS; Chae D
    Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations.
    Schaedeli Stark F; Chavanne C; Derks M; Jolling K; Lagraauw HM; Lindbom L; Prins K; Silber Baumann HE
    J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):227-242. PubMed ID: 38308741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D printing combined with biopredictive dissolution and PBPK/PD modeling optimization and personalization of pharmacotherapy: Are we there yet?
    Wyszogrodzka-Gaweł G; Shuklinova O; Lisowski B; Wiśniowska B; Polak S
    Drug Discov Today; 2023 Oct; 28(10):103731. PubMed ID: 37541422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.